Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: ENZAMET

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516137-13-00

Acronym

CTRIAL-IE 14-06

Enrollment

Registered

2024-10-08

Start date

2014-12-18

Completion date

Unknown

Last updated

2025-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Prostate Cancer

Brief summary

Overall survival (death from any cause)

Detailed description

Prostate specific antigen progression free survival (PCGW2), Clinical progression free survival (imaging, symptoms, signs), Adverse events (CTCAE v4.03), Health related quality of life (EORTC QLQ C-30, PR-25 and EQ-5D-5L), Health outcomes relative to costs (incremental cost effectiveness ratio)

Interventions

DRUGXtandi - 40 mg soft capsules

DRUGFlutamide 250 mg Tablets

DRUGCasodex® 50 mg Film-coated Tablets

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall survival (death from any cause)	—

Secondary

Measure	Time frame
Prostate specific antigen progression free survival (PCGW2), Clinical progression free survival (imaging, symptoms, signs), Adverse events (CTCAE v4.03), Health related quality of life (EORTC QLQ C-30, PR-25 and EQ-5D-5L), Health outcomes relative to costs (incremental cost effectiveness ratio)	—

Countries

Ireland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026